Literature DB >> 11075838

Determinants of patient satisfaction with migraine therapy.

G M Davies1, N Santanello, R Lipton.   

Abstract

Determinants of patient satisfaction with migraine treatment are not well understood. The objective of this study was to evaluate which treatment outcomes influence patient satisfaction with treatment. Analyses were performed on data from 1506 migraineurs from two clinical trials of rizatriptan for treatment of migraine. Satisfaction with treatment was assessed 2 h after initial treatment and prior to use of rescue therapy. Over 90% of patients who were pain-free at 2 h were at least somewhat satisfied with treatment compared with <10% of patients with moderate or severe pain. Only 60-70% of patients with mild pain at 2 h experienced some level of satisfaction with treatment. For patients with mild pain at 2 h, results showed subjects who reported severe pain at baseline, absence of associated symptoms at 2 h and pain relief within the first 90 min had at least a 76% probability of being at least somewhat satisfied. This probability decreased with the presence of associated symptoms, slower pain relief and moderate baseline pain intensity. Fast, complete pain relief is one important factor in determining short-term patient satisfaction with treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11075838     DOI: 10.1046/j.1468-2982.2000.00082.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  29 in total

Review 1.  Meeting acute migraine treatment needs through novel treatment formulations.

Authors:  Stephen D Silberstein
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

Review 2.  Assessing the efficacy of drugs for the acute treatment of migraine: issues in clinical trial design.

Authors:  Nabih M Ramadan
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

3.  Development and psychometric validation of a new patient satisfaction instrument: the osteoARthritis Treatment Satisfaction (ARTS) questionnaire.

Authors:  J Pouchot; E Trudeau; S C Hellot; G Meric; A Waeckel; J Goguel
Journal:  Qual Life Res       Date:  2005-06       Impact factor: 4.147

4.  Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine.

Authors:  David W Dodick; Giorgio Sandrini; Paul Williams
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 5.  Prioritizing treatment attributes and their impact on selecting an oral triptan: results from the TRIPSTAR Project.

Authors:  David W Dodick; Richard B Lipton; Michel D Ferrari; Peter J Goadsby; Douglas McCrory; F Michael Cutrer; Paul Williams
Journal:  Curr Pain Headache Rep       Date:  2004-12

6.  The medical care utilization and costs associated with migraine headache.

Authors:  Jennifer Elston Lafata; Christina Moon; Carol Leotta; Ken Kolodner; Laila Poisson; Richard B Lipton
Journal:  J Gen Intern Med       Date:  2004-10       Impact factor: 5.128

7.  Adherence to headache treatment and profile of previous health professional seeking among patients with chronic headache: a retrospective analysis.

Authors:  Abouch Valenty Krymchantowski; Marcus Vinicius Adriano; Renemilda de Góes; Pedro Ferreira Moreira; Carla da Cunha Jevoux
Journal:  MedGenMed       Date:  2007-04-26

8.  Treatment satisfaction after switching to another therapy in Spanish orthopaedic clinic outpatients with knee or hip osteoarthritis previously refractory to paracetamol.

Authors:  Angel Oteo-Álvaro; María T Marín; Miguel A Ruiz-Ibán; Beatriz Armada; Javier Rejas
Journal:  Clin Drug Investig       Date:  2012-10-01       Impact factor: 2.859

9.  Prophylaxis of migraine.

Authors:  Ivan Garza; Jerry W Swanson
Journal:  Neuropsychiatr Dis Treat       Date:  2006-09       Impact factor: 2.570

10.  Treatment satisfaction and efficacy of the rapid release formulation of sumatriptan 100 mg tablets utilising an early intervention paradigm in patients previously unsatisfied with sumatriptan.

Authors:  L C Newman; R K Cady; S Landy; P O'Carroll; W J Kwong; S P Burch; A C Nelsen; S A McDonald
Journal:  Int J Clin Pract       Date:  2008-12       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.